In patients with cardiogenic shock, no significant difference between Milrinone and Dobutamine was found with respect to the primary composite outcome or important secondary outcomes.

A total of 192 participants (96 in each group) were enrolled.

The treatment groups did not differ significantly with respect to the primary outcome; a primary outcome event occurred in 47 participants (49%) in the Milrinone group and in 52 participants (54%) in the Dobutamine group.

There were also no significant differences between the groups with respect to secondary outcomes, including in-hospital death, resuscitated cardiac arrest, receipt of mechanical circulatory support, or initiation of renal replacement therapy.

Read More